Drug
Lenvatinib Oral Product
Lenvatinib Oral Product is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(20%)
Phase Distribution
Ph phase_2
2
40%
Ph not_applicable
2
40%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Other(4)
Detailed Status
unknown4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (50.0%)
N/A2 (50.0%)
Trials by Status
active_not_recruiting120%
unknown480%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingphase_2
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
NCT04869137
unknownphase_2
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT05935579
unknown
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
NCT05420922
unknownnot_applicable
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
NCT04425226
unknownnot_applicable
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
NCT04444193
Clinical Trials (5)
Showing 5 of 5 trials
NCT04869137Phase 2
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
NCT05935579Phase 2
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT05420922
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
NCT04425226Not Applicable
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
NCT04444193Not Applicable
Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5